What question did this study set out to answer?

To determine whether the cardiac glycoside ouabain modulates the production of inflammatory cytokines in vitro and protects against endotoxin-induced lethality in vivo.

September 2, 1997Circulation

Modulation of Cytokine Production and Protection Against Lethal Endotoxemia by the Cardiac Glycoside Ouabain

View Full Paper

Ask AI

Bookmark

Authors

AMAkira Matsumori KOKoh Ono RNRyosuke Nishio

Discussion

Member takes

Overview

Ouabain shows context-dependent cytokine effects and endotoxemia protection in models; leaves open relevance to glycoside therapy in heart failure.

Key Points

To determine whether the cardiac glycoside ouabain modulates the production of inflammatory cytokines in vitro and protects against endotoxin-induced lethality in vivo.
Cultured human peripheral blood mononuclear cells (PBMC) with or without ouabain in the presence or absence of lipopolysaccharide (LPS), using kinase inhibitors to probe intracellular pathways.
Administered ouabain to LPS-treated mice to evaluate survival rates and circulating levels of IL-6 and TNF-alpha in vivo.
In resting human PBMC, ouabain induced mRNA transcription and protein release of IL-1beta, IL-6, and TNF-alpha, mediated via protein kinase C and tyrosine kinase pathways.
In LPS-stimulated human PBMC, ouabain conversely suppressed the production of IL-6 and TNF-alpha.
In vivo, ouabain reduced circulating IL-6 and TNF-alpha concentrations and protected mice against LPS-induced lethal toxicity.

Cite This Study

Matsumori et al. (1997) studied this question.

synapsesocial.com/papers/6a712ca435aa2c282ce27d1d https://doi.org/10.1161/01.cir.96.5.1501

View Full Paper

Ask AI

Bookmark

September 2, 1997Circulation

Modulation of Cytokine Production and Protection Against Lethal Endotoxemia by the Cardiac Glycoside Ouabain

View Full Paper

Ask AI

Bookmark

Authors

AMAkira Matsumori KOKoh Ono RNRyosuke Nishio

Discussion

Member takes

Overview

Ouabain shows context-dependent cytokine effects and endotoxemia protection in models; leaves open relevance to glycoside therapy in heart failure.

Key Points

To determine whether the cardiac glycoside ouabain modulates the production of inflammatory cytokines in vitro and protects against endotoxin-induced lethality in vivo.
Cultured human peripheral blood mononuclear cells (PBMC) with or without ouabain in the presence or absence of lipopolysaccharide (LPS), using kinase inhibitors to probe intracellular pathways.
Administered ouabain to LPS-treated mice to evaluate survival rates and circulating levels of IL-6 and TNF-alpha in vivo.
In resting human PBMC, ouabain induced mRNA transcription and protein release of IL-1beta, IL-6, and TNF-alpha, mediated via protein kinase C and tyrosine kinase pathways.
In LPS-stimulated human PBMC, ouabain conversely suppressed the production of IL-6 and TNF-alpha.
In vivo, ouabain reduced circulating IL-6 and TNF-alpha concentrations and protected mice against LPS-induced lethal toxicity.

Cite This Study

Matsumori et al. (1997) studied this question.

synapsesocial.com/papers/6a712ca435aa2c282ce27d1d https://doi.org/10.1161/01.cir.96.5.1501

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark